- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02824536
3BNC117 and 10-1074 in HIV Uninfected Adults
A Phase 1 Study of the Safety and Pharmacokinetics of the Combination of 3BNC117 and 10-1074 in HIV-uninfected Adults
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study will be conducted under a placebo-controlled, double blind, randomized allocation of the study products. Study participants in each study group will be randomized to receive intravenous infusions of 3BNC117 and 10-1074 or placebo. 3BNC117 and 10-1074 will be administered at 2 dose levels (3 mg/kg and 10 mg/kg). These doses were selected based on the planned development of subcutaneous formulations for the prophylactic use of these products. The study will consist of 3 groups. Enrollment in Group 1 will begin first and participants will be enrolled at least one day apart. Eight participants will be enrolled in each group; 6 will be randomized receive the study drugs and 2 will be randomized to receive placebo. Participants in Group 1 will receive a single infusion of each antibody at 10mg/kg at Week 0. Enrollment in Group 2 will begin only after Day 28 safety data from all participants in Group 1, including ophthalmologic exams, are available. Enrollment in Group 3 will begin only after the Day 28 safety data from all participants in Group 2 is available. If > 1 grade 3 or higher adverse events deemed probably or definitely related to the study drugs occurs in a single group, the next group will not be enrolled pending safety monitoring committee (SMC) review. Participants in Groups 2 and 3 will receive 3 infusions of each antibody at Weeks 0, 8, and 16, at a dose of either 3mg/kg or 10mg/kg. The antibodies will be administered sequentially via intravenous infusion. Each antibody will be administered over 60 minutes.
Following product infusions, study participants will return for safety assessments at multiple time points. Blood samples will be collected for safety testing at weeks 1, 2, and 4 following each infusion, then at multiple time points until the end of study follow up.
Baseline pharmacokinetic (PK) assessments will be performed before the start of the first infusion. Peak PK sampling for 3BNC117 will occur following the completion of the 3BNC117 infusion prior to the start of the 10-1074 infusion. Peak PK sampling for 10-1074 will occur following the completion of the 10-1074 infusion. Additional PK assessments will occur at multiple time points during study follow up. Study participants will be followed for a total of 24 weeks following the final antibody infusion.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10065
- The Rockefeller University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Males and females, age 18 to 65.
- Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent with low risk of HIV exposure.
- If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception (i.e. condom with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based contraceptive with condom) for the duration of the study.
Exclusion Criteria:
- Confirmed HIV-1 or HIV-2 infection.
- History of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months.
- Any clinically significant acute or chronic medical condition (such as autoimmune diseases) that in the opinion of the investigator would preclude participation.
- Within the 12 months prior to enrollment, the participant has a history of sexually transmitted infection.
- Chronic Hepatitis B or Hepatitis C infection.
- Laboratory abnormalities in the parameters listed:
- Absolute neutrophil count ≤ 2,000;
- Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male;
- Platelet count ≤ 125,000;
- Alanine Aminotransferase (ALT) ≥ 1.25 x ULN; Aspartate Aminotransferase (AST) ≥ 1.25 x ULN;
- Alkaline phosphatase ≥ 1.5 x ULN
- Total bilirubin > 1.0 x ULN;
- Creatinine ≥1.1 x ULN;
- Pregnancy or lactation.
- Any vaccination within 14 days prior to infusion
- Receipt of any experimental HIV vaccine in the past.
- History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions.
- Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Group 1
Participants will be randomized in a 3:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
|
Infusión intravenosa de 3BNC117
Otros nombres:
Intravenous Infusion of 10-1074
Otros nombres:
Intravenous Infusion of Sterile Saline (NaCl 0.9%)
Otros nombres:
|
Experimental: Group 2
Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 3 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
|
Infusión intravenosa de 3BNC117
Otros nombres:
Intravenous Infusion of 10-1074
Otros nombres:
Intravenous Infusion of Sterile Saline (NaCl 0.9%)
Otros nombres:
|
Experimental: Group 3
Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
|
Infusión intravenosa de 3BNC117
Otros nombres:
Intravenous Infusion of 10-1074
Otros nombres:
Intravenous Infusion of Sterile Saline (NaCl 0.9%)
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
The number of participants who experience adverse events within 1 week after the combination of 3BNC117 and 10-1074 infusion in all study groups.
Periodo de tiempo: 1 week following each combination of 3BNC117 and 10-1074 infusion
|
Adverse events include signs, symptoms and laboratory abnormalities, in addition to local and systemic reactogenicity adverse events.
|
1 week following each combination of 3BNC117 and 10-1074 infusion
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of participants with induced anti-3BNC117 and anti-10-1074 antibodies
Periodo de tiempo: 8 weeks following each combination of 3BNC117 and 10-1074 infusion
|
8 weeks following each combination of 3BNC117 and 10-1074 infusion
|
|
Level of induced anti-3BNC117 and anti-10-1074 antibodies
Periodo de tiempo: 8 weeks following each combination of 3BNC117 and 10-1074 infusion
|
8 weeks following each combination of 3BNC117 and 10-1074 infusion
|
|
The number of participants who experience adverse events that occur during study follow up after 3BNC117 and 10-1074 infusions in all study groups.
Periodo de tiempo: 24-40 weeks
|
Adverse events include signs, symptoms and laboratory abnormalities.
|
24-40 weeks
|
Otras medidas de resultado
Medida de resultado |
Periodo de tiempo |
---|---|
Neutralization activity of serum from study participants against a panel of viruses as measured by the TZM.bl neutralization assay.
Periodo de tiempo: 24-40 weeks
|
24-40 weeks
|
Elimination half-life (t1/2) of 3BNC117 and 10-1074
Periodo de tiempo: 24-40 weeks
|
24-40 weeks
|
Clearance (CL/F) of 3BNC117 and 10-1074
Periodo de tiempo: 24-40 weeks
|
24-40 weeks
|
Volume of distribution (Vz/F) of 3BNC117 and 10-1074
Periodo de tiempo: 24-40 weeks
|
24-40 weeks
|
Area under the plasma concentration versus time curve (AUC) of 3BNC117 and 10-1074
Periodo de tiempo: 24-40 weeks
|
24-40 weeks
|
Decay Curve of of 3BNC117 and 10-1074
Periodo de tiempo: 24-40 weeks
|
24-40 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Yehuda Cohen, MD, Rockefeller University
Publicaciones y enlaces útiles
Publicaciones Generales
- Valente PK, Wu Y, Cohen YZ, Caskey M, Meyers K. Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention. Clin Trials. 2021 Feb;18(1):17-27. doi: 10.1177/1740774520948042. Epub 2020 Aug 24.
- Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O'Brien C, Patel R, Shimeliovich I, Lorenzi JCC, Horowitz J, Walsh SR, Lin S, Weiner JA, Tse A, Sato A, Bennett C, Mayer B, Seaton KE, Yates NL, Baden LR, deCamp AC, Ackerman ME, Seaman MS, Tomaras GD, Nussenzweig MC, Caskey M. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS One. 2019 Aug 8;14(8):e0219142. doi: 10.1371/journal.pone.0219142. eCollection 2019.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Enfermedades de virus lentos
- Infecciones por VIH
- Síndrome de inmunodeficiencia adquirida
- Efectos fisiológicos de las drogas
- Agentes antineoplásicos
- Factores inmunológicos
- Anticuerpos
- Inmunoglobulinas
- Anticuerpos Monoclonales
- Agentes antineoplásicos inmunológicos
Otros números de identificación del estudio
- YCO-0899
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Virus de inmunodeficiencia humana
-
The AlfredMerck Sharp & Dohme LLCTerminadoInfección por el virus del papiloma humano | Virus del papiloma humanoAustralia
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention; American Cancer Society, Inc.; New... y otros colaboradoresRetiradoInfección por el virus del papiloma humanoEstados Unidos
-
Merck Sharp & Dohme LLCTerminadoInfección por el virus del papiloma humano
-
Sanford HealthTerminadoInfección por el virus del papiloma humanoEstados Unidos
-
GlaxoSmithKlineTerminadoInfección por el virus del papiloma humanoBaréin
-
Kanazawa Medical UniversityMerck Sharp & Dohme LLCDesconocidoInfecciones por virus del papiloma | Vacunas contra el virus del papiloma
-
H. Lee Moffitt Cancer Center and Research InstituteTerminadoInfección por el virus del papiloma humanoEstados Unidos
-
CHU de Quebec-Universite LavalCentre hospitalier de l'Université de Montréal (CHUM); Institut National en Santé... y otros colaboradoresTerminadoInfecciones por el virus del papiloma humanoCanadá
-
Centre Hospitalier Universitaire de BesanconTerminadoInfección por el virus del papiloma humanoFrancia
-
University Hospital, GenevaTerminadoInfección por el virus del papiloma humanoSuiza
Ensayos clínicos sobre 3BNC117
-
University of Lausanne HospitalsTerminado
-
Rockefeller UniversityTerminadoInfección por VIH-1Estados Unidos
-
Rockefeller UniversityBrigham and Women's Hospital; Weill Medical College of Cornell University; University...TerminadoSaludable | VIHEstados Unidos, Alemania
-
Frontier Biotechnologies Inc.Desconocido
-
International AIDS Vaccine InitiativeBrigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller UniversityActivo, no reclutandoInfección por VIH-1Estados Unidos, Uganda, Kenia, Ruanda, Sudáfrica
-
Rockefeller UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... y otros colaboradoresTerminadoInfección por VIH-1Estados Unidos
-
Advancing Clinical Therapeutics Globally for HIV...National Institute of Allergy and Infectious Diseases (NIAID)Aún no reclutando
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)Aún no reclutandoInfección por VIH-1Malaui, Sudáfrica, Botsuana
-
Rockefeller UniversityTerminado
-
National Institute of Allergy and Infectious Diseases...Rockefeller UniversityRetiradoInfecciones por VIHEstados Unidos